Histone deacetylase inhibitor, mocetinostat, regulates cardiac remodelling and renin-angiotensin system activity in rats with transverse aortic constriction-induced pressure overload cardiac hypertrophy
Autor: | Hanna Jung, Sung Woon Chung, Gun-Jik Kim, Eunjo Lee |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
kidney hypertension Mocetinostat medicine.drug_class Cardiomegaly heart Muscle hypertrophy Renin-Angiotensin System chemistry.chemical_compound Fibrosis Internal medicine Renin–angiotensin system medicine Renal fibrosis Diseases of the circulatory (Cardiovascular) system Animals Humans Pressure overload Ventricular Remodeling business.industry animal model Myocardium Histone deacetylase inhibitor General Medicine medicine.disease Angiotensin II Constriction Rats Histone Deacetylase Inhibitors Endocrinology Pyrimidines chemistry RC666-701 histone deacetylase Benzamides cardiovascular system Cardiology and Cardiovascular Medicine business hypertrophy |
Zdroj: | Reviews in Cardiovascular Medicine, Vol 22, Iss 3, Pp 1037-1045 (2021) |
ISSN: | 1530-6550 |
Popis: | Histone deacetylase (HDAC) inhibitors have shown cardioprotective or renoprotective effects in various animal models. Our study proposed that the HDAC inhibitor, mocetinostat, regulates cardiac remodelling and renin-angiotensin system (RAS) activity in rats with transverse aortic constriction (TAC)-induced pressure overload cardiac hypertrophy. Cardiac remodelling was evaluated using echocardiography. Cardiac hypertrophy was visualized with haematoxylin and eosin staining, and related gene (Nppa and Nppb) expression was quantified by quantitative real-time polymerase chain reaction (qRT-PCR). Cardiac and renal fibrosis were visualized with picrosirius red and trichrome staining, respectively. Fibrosis related gene (Collagen-1, Collagen-3, Ctgf, and Fibronectin) expression was determined by qRT-PCR. Serum concentrations of RAS components (renin, angiotensin II, and aldosterone) were quantified by enzyme-linked immunosorbent assay and related gene (Renin and Agtr1) expression was determined by qRT-PCR. TAC-induced pressure overload cardiac hypertrophy, which mimics hypertensive heart disease, increased cardiac remodelling, cardiac hypertrophy, and fibrosis in our rat models. Upon treatment with mocetinostat, there was a significant regression in cardiac remodelling, cardiac hypertrophy, and fibrosis in TAC rats. Additionally, pressure overload-induced renal fibrosis and activity of RAS-related components were increased in TAC rats, and were decreased on treatment with mocetinostat. The present study indicates that mocetinostat, an HDAC inhibitor, has cardiorenal protective effects in rats with TAC-induced pressure overload cardiac hypertrophy and offers a promising therapeutic agent for hypertension-related diseases. |
Databáze: | OpenAIRE |
Externí odkaz: |